Luye Pharma Group Ltd. (2186.HK)

HKD 2.17

(-2.25%)

Market Cap (In HKD)

8.16 Billion

Revenue (In HKD)

6.14 Billion

Net Income (In HKD)

532.6 Million

Avg. Volume

8.46 Million

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.14-3.77
PE
-
EPS
-
Beta Value
0.854
ISIN
BMG570071099
CUSIP
G57007109
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Dian Bo Liu
Employee Count
-
Website
https://www.luye.cn
Ipo Date
2014-07-09
Details
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.